Chugai Of Japan Reveals Deaths In Local Study Of Arthritis Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical, now a subsidiary of Roche, has disclosed its Actemra (tocilizumab) drug for treating rheumatoid arthritis may be connected with the deaths of 15 patients. The company did not deny a connection between its drug and the deaths, but said it would supply more information to physicians about side effects. The study in which the deaths occurred involved nearly 5,000 people in Japan where the study was required after it was approved. The drug also has EU approval, but not in the United States. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.